Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.
about
Conjugate vaccines for preventing meningococcal C meningitis and septicaemiaConjugate vaccines for preventing meningococcal C meningitis and septicaemiaPhase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.Importance of complement source in measuring meningococcal bactericidal titers.Control and lot release of meningococcal group C conjugate vaccines.Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiencyExperience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.Routinely vaccinating adolescents against meningococcus: targeting transmission & diseaseGenetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youthBinding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.Neisseria meningitidis B vaccines.Advances with vaccination against Neisseria meningitidis.Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.Meningococcal polysaccharide vaccine failure in a patient with C7 deficiency and a decreased anti-capsular antibody response.Serogroup A meningococcal conjugate vaccines in Africa.Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine.Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.
P2860
Q24235722-312DAEBC-01DD-4044-9BEB-52F2ABD62DF7Q24244951-DFD12961-7511-4CF5-8E7E-54C75791277BQ33844571-1430CEE6-F1E4-4EC1-BB22-881BB1903B3EQ33999159-DDFB08F1-309D-460A-9E9E-EFD7D167E6D3Q35918490-1D924E43-91E2-4D71-B530-DE1349EA49CCQ36539053-42961CC4-938B-4485-B82D-AD78DB7F4B6AQ36600323-E10994EC-515B-42BC-B92A-99A56C2A5B21Q36781534-673CF958-C4E0-45B4-8D51-E08684D33096Q36825737-D613C489-B1F0-4291-98A4-11DF7597AB35Q36911285-4123ACD9-2D99-44E9-94E5-C8B120A4E768Q37075472-ABE2CE7B-5D42-4647-8219-D337EBBA06C7Q37362174-813F18F8-A150-4BFB-A3C5-424410141CEAQ37523580-607E1DB1-59AA-4C5D-A8AD-F4CABD95F127Q37932528-972A4F13-5631-4143-8764-548C22524179Q38040527-74FA1267-94C7-46D6-BCA1-1FB0FE335AE1Q38367830-072DDA1A-F8A0-4368-8E6E-2C3D8336DC55Q38403260-633CAB1C-F5B7-44F3-8214-2E7C604E060CQ38584375-1791E269-072A-4749-BD02-7B03A549B926Q38870793-983AB6FC-C26C-4970-B79A-C63CE34829C6Q39852648-460DEB14-7705-4D9A-A090-C1743B1EEBDC
P2860
Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Standardisation and validation ...... is serogroup A and C vaccines.
@ast
Standardisation and validation ...... is serogroup A and C vaccines.
@en
Standardisation and validation ...... is serogroup A and C vaccines.
@nl
type
label
Standardisation and validation ...... is serogroup A and C vaccines.
@ast
Standardisation and validation ...... is serogroup A and C vaccines.
@en
Standardisation and validation ...... is serogroup A and C vaccines.
@nl
prefLabel
Standardisation and validation ...... is serogroup A and C vaccines.
@ast
Standardisation and validation ...... is serogroup A and C vaccines.
@en
Standardisation and validation ...... is serogroup A and C vaccines.
@nl
P2093
P356
P1433
P1476
Standardisation and validation ...... is serogroup A and C vaccines.
@en
P2093
I M Feavers
K Cartwright
P304
P356
10.1006/BIOL.2000.0253
P577
2000-09-01T00:00:00Z